Search Results - Collaboration+Sought+%3e+Licensing

1108 Results

Sort By:

Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy

Summary: The National Cancer Institute (NCI) seeks capable licensees interested in commercializing T cell receptor (TCR)-engineered T cells expressing murine/human hybrid receptors. Description of Technology: TCR-T therapies, particularly those targeting patient-specific neoantigens, remain a promising approach to the treatment metastatic cancers....

Published: 8/25/2025 | Inventor(s): Steven Feldman, Steven Rosenberg, Drew Deniger

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a set of Chimeric Antigen Receptors (CARs) that target the γδ T-Cell Receptor. Description of Technology: T cells express two main types of receptors based on the proteins that make up the T-cell receptor (TCR) heterodimers: ab (alpha...

Published: 8/25/2025 | Inventor(s): James Kochenderfer, Lauren Cutmore

Keywords(s):

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s)

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for development of papilloma-infiltrating lymphocytes (PIL) as treatment for patients with chronic human papillomavirus (HPV) 6 or 11 infections. Description of Technology: Recurrent Respiratory Papillomatosis (RRP) and anogenital condyloma are caused...

Published: 8/21/2025 | Inventor(s): Scott Norberg, Clint Allen, Zulmarie Franco, Ke Bai

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof

Summary: The National Cancer Institute (NCI) and Frederick National Laboratory for Cancer Research (FNLCR) seek research co-development partners and/or licensees for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for recurrent respiratory papillomatosis (RRP). Description of Technology: Recurrent...

Published: 8/21/2025 | Inventor(s): Scott Norberg, Clint Allen, Xiaolin Wu

Keywords(s):

Category(s): TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, TherapeuticArea > Pulmonology, Application > Diagnostics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

C8166-45 Cells

Summary: The National Cancer Institute (NCI) seeks licensees for a human T-cell line, C8166-45, transformed by HTLV-1. C8166-45, also known as C63/CRII-2, contains three transcriptionally active proviruses useful for testing biological activities involved in T-cell immortalization and growth. Description of Technology: ...

Published: 8/21/2025 | Inventor(s): Genoveffa Franchini, Syed Salahuddin, Flossie Wong-Staal, Robert Gallo, Phillip Markham, V Kalyanaraman

Keywords(s):

Category(s): Application > Research Materials, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Chimeric VLP vaccines to Prevent HTLV-1 Infection

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for Chimeric VLP Vaccines to Prevent HTLV-1 Infection. Description of Technology: There is currently no approved vaccine to prevent human T-cell leukemia virus type I (HTLV-1) infection, a highly oncogenic virus linked to serious diseases like adult...

Published: 8/12/2025 | Inventor(s): Genoveffa Franchini, Sarkis Sarkis, Ramona Moles, Cynthia Masison, Massimiliano Bissa

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies

Summary: The National Cancer Institute (NCI) seeks licensees for this invention comprising (1) a novel T cell receptor (TCR) specific to the E2 protein of Human papillomavirus (HPV) type 6 in the context of the human leukocyte antigen, HLA-B55, and (2) a panel of Cos7 cells expressing different HLA proteins for validation of T cell responses in immunotherapies...

Published: 8/21/2025 | Inventor(s): Clint Allen, Scott Norberg

Keywords(s):

Category(s): Application > Research Materials, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Collaboration Sought > Licensing

A conserved viral peptide for use in cancer immunotherapy

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for viral peptide (CE1)-based therapeutics for HCC prevention and treatment. Description of Technology: Hepatocellular carcinoma (HCC) is a common and aggressive primary liver cancer. It develops mainly from at-risk individuals with underlying chronic...

Published: 8/21/2025 | Inventor(s): Xin Wei Wang, Lichun Ma, Man Hsin Hung

Keywords(s):

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy

Summary: The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for NCI’s compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines. Description of Technology: Current dendritic cell (DC)-based cancer vaccines are limited by impaired DC function due to cancer-driven...

Published: 8/21/2025 | Inventor(s): Jay Berzofsky, Shweta Tiwary

Keywords(s):

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Anti-Nucleoprotein Crimean-Congo Hemorrhagic Fever Virus Monoclonal Antibodies for Assay Creation

Crimean-Congo hemorrhagic fever (CCHF) is the most widespread form of viral hemorrhagic fever, found in Eastern and Southern Europe, the Mediterranean, northwestern China, central Asia, Africa, the Middle East, and the Indian subcontinent. Typically beginning with non-specific fever, myalgia, nausea, diarrhea, and general malaise, symptoms of infection...

Published: 7/3/2025 | Inventor(s): Daniel Douek, David Hawman, Leonid Serebryannyy, Noemia Santana Lima, Chaim Schramm, Sarah Smith (Kerscher), Amy Henry, Alicen Spaulding

Keywords(s):

Category(s): Application, Application > Diagnostics, Collaboration Sought, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Antibodies, TherapeuticArea, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, TherapeuticArea > Rare/Neglected Diseases

1 2 3 4 5 6 7 8 9 10 ...